Givaudan Past Earnings Performance
Past criteria checks 5/6
Givaudan has been growing earnings at an average annual rate of 6.8%, while the Chemicals industry saw earnings growing at 9.6% annually. Revenues have been growing at an average rate of 3.5% per year. Givaudan's return on equity is 23.9%, and it has net margins of 14.5%.
Key information
6.8%
Earnings growth rate
6.8%
EPS growth rate
Chemicals Industry Growth | 12.4% |
Revenue growth rate | 3.5% |
Return on equity | 23.9% |
Net Margin | 14.5% |
Next Earnings Update | 24 Jan 2025 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Givaudan makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 7,117 | 1,032 | 1,146 | 537 |
31 Mar 24 | 7,016 | 963 | 1,126 | 528 |
31 Dec 23 | 6,915 | 893 | 1,105 | 519 |
30 Sep 23 | 6,958 | 879 | 1,106 | 518 |
30 Jun 23 | 7,000 | 865 | 1,106 | 516 |
31 Mar 23 | 7,059 | 861 | 1,109 | 519 |
31 Dec 22 | 7,117 | 856 | 1,112 | 522 |
30 Sep 22 | 7,040 | 818 | 1,130 | 538 |
30 Jun 22 | 6,963 | 780 | 1,148 | 553 |
31 Mar 22 | 6,824 | 801 | 1,157 | 558 |
31 Dec 21 | 6,684 | 821 | 1,165 | 562 |
30 Sep 21 | 6,579 | 816 | 1,145 | 557 |
30 Jun 21 | 6,474 | 811 | 1,124 | 552 |
31 Mar 21 | 6,398 | 777 | 1,098 | 544 |
31 Dec 20 | 6,322 | 743 | 1,072 | 536 |
30 Sep 20 | 6,326 | 739 | 1,063 | 533 |
30 Jun 20 | 6,330 | 735 | 1,054 | 530 |
31 Mar 20 | 6,267 | 719 | 1,038 | 529 |
31 Dec 19 | 6,203 | 702 | 1,021 | 528 |
30 Sep 19 | 6,075 | 687 | 1,000 | 520 |
30 Jun 19 | 5,947 | 672 | 978 | 512 |
31 Mar 19 | 5,737 | 668 | 956 | 495 |
31 Dec 18 | 5,527 | 663 | 934 | 477 |
30 Sep 18 | 5,385 | 685 | 914 | 460 |
30 Jun 18 | 5,242 | 707 | 894 | 442 |
31 Mar 18 | 5,147 | 714 | 877 | 433 |
31 Dec 17 | 5,051 | 720 | 859 | 424 |
30 Sep 17 | 4,932 | 690 | 849 | 417 |
30 Jun 17 | 4,812 | 660 | 839 | 409 |
31 Mar 17 | 4,738 | 652 | 839 | 405 |
31 Dec 16 | 4,663 | 644 | 839 | 400 |
30 Sep 16 | 4,605 | 648 | 829 | 390 |
30 Jun 16 | 4,546 | 651 | 819 | 380 |
31 Mar 16 | 4,471 | 638 | 806 | 373 |
31 Dec 15 | 4,396 | 625 | 793 | 366 |
30 Sep 15 | 4,397 | 613 | 800 | 378 |
30 Jun 15 | 4,397 | 600 | 807 | 390 |
31 Mar 15 | 4,401 | 582 | 815 | 398 |
31 Dec 14 | 4,404 | 563 | 823 | 405 |
30 Sep 14 | 4,370 | 544 | 820 | 404 |
30 Jun 14 | 4,335 | 524 | 817 | 403 |
31 Mar 14 | 4,352 | 507 | 809 | 405 |
31 Dec 13 | 4,369 | 490 | 801 | 406 |
Quality Earnings: GIN1 has high quality earnings.
Growing Profit Margin: GIN1's current net profit margins (14.5%) are higher than last year (12.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GIN1's earnings have grown by 6.8% per year over the past 5 years.
Accelerating Growth: GIN1's earnings growth over the past year (19.3%) exceeds its 5-year average (6.8% per year).
Earnings vs Industry: GIN1 earnings growth over the past year (19.3%) exceeded the Chemicals industry 7.2%.
Return on Equity
High ROE: Whilst GIN1's Return on Equity (23.93%) is high, this metric is skewed due to their high level of debt.